<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615938</url>
  </required_header>
  <id_info>
    <org_study_id>EudratCT:2013-003714-40</org_study_id>
    <nct_id>NCT02615938</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)</brief_title>
  <acronym>HCQ-chILD-EU</acronym>
  <official_title>Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled,&#xD;
      parallel-group, multinational study investigating the initiation or withdrawal of&#xD;
      hydroxychloroquine in subjects with chILD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an explorative, prospective, randomized, double-blind, placebo controlled&#xD;
      investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in&#xD;
      START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each&#xD;
      patient can participate in each block only once. In the START block subjects are randomized&#xD;
      to parallel-groups, then the placebo group is switched to active drug. In the STOP block,&#xD;
      subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to&#xD;
      investigate the withdrawal of HCQ for assessment of its efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Correction of inspection findings&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Oxygenation</measure>
    <time_frame>Start HCQ block: 28 and 56 days; Stop HCQ block: 84 days</time_frame>
    <description>Start HCQ block: relative Change Trial day 1 through day 28 and relative Change day 28 to day 56; Change active compound compared to Change Placebo.&#xD;
Stop HCQ block: Relative change trail day 1 through day 84: change active compound compared to change Placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Oxygen Saturation</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(O2-sat, in room air) (only absolute, as relative already Primary outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Respiratory rate</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(RR, in room air) (relative and absolute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Retraction, Coughing</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lab values</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(GOT, Creatinine, gGT, blood count, differential, LDH, potassium, steady state drug level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oxygen demand</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>in room air, on Os-supplement or O2 flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QoL</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(PedsQl™ generic and chILD specific module)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Health economics</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>specific questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Overall survival</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>death or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Weight to Height ratio</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Weight measured in kg and Height measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amounts of Steroid equivalents</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Clinical course of lung disease (since last visit): Healthy/ Sick-better/ Sick-same/ Sick-worse/ Patient died</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of x-ray</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>if x-ray were done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pO2, pCO2</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(capillary, in room air)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pulmonary exacerbation</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(since last visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Forced vital capacity</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured by spirometry or bodyplethysmography; If &gt; 5y old (If a child ≤ 5 years is already able to perform the listed investigations (spirometry or bodyplethysmography), these should also be performed and documented at the discretion of the investigator.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of abnormal changes in Electrocardiographie (ECG)</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured on start and end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 6 minute walking distance (6MWT) (in meter)</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>O2-saturation will be measured before and after 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Borg Scale</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Measured after 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with ophthalmologic abnormalities</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Ophthalmologic review on start and end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment related advers events</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured on each visit</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Diffuse Parenchymal Lung Disease</condition>
  <condition>Children´s Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Placebo for 3 months and will be followed up for additional 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine sulfate</intervention_name>
    <description>Apply drug to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <other_name>Quensyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Apply Placebo not to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients should be clinically stable during baseline (between Visit 1 and 2) for&#xD;
             inclusion into the study&#xD;
&#xD;
               1. To determine this, attending physicians can use SpO2 in room air for patients on&#xD;
                  room air or on O2-supplement; the absolute difference on SpO2 is expected not to&#xD;
                  be ≥ 5% between Visit 1 and 2. For patients on respiratory support, the summary&#xD;
                  key parameters should not change ≥ 20% between Visit 1 and 2 and&#xD;
&#xD;
               2. No major changes in other medications between Visit 1 and 2&#xD;
&#xD;
          2. Mature newborn ≥ 37 weeks of gestation, age ≥ 3 wks and &lt;2y or Infants and children&#xD;
             (≥2y and &lt; 18y) or Adults (≥18 and ≤30y) or Previously preterm (≤ 37 weeks of&#xD;
             gestation) babies or children and adults of all ages if chILD genetically diagnosed&#xD;
             (see inclusion criterion 3.)&#xD;
&#xD;
          3. Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD =&#xD;
             chILD), defined in at least one of the following ways:&#xD;
&#xD;
               1. chILD genetically diagnosed Surfactant dysfunction disorders including patients&#xD;
                  with mutations in SFTPC, SFTPB, ABCA3, TTF1 (Nkx2-1), further extremely rare&#xD;
                  entities with specific mutations, for example in TBX4, NPC2, NPC1, NPB, COPA,&#xD;
                  LRBA and other genes. In this case, also previously preterm (≤ 37 weeks of&#xD;
                  gestation) babies or children and adults of all ages can be included into the&#xD;
                  study.&#xD;
&#xD;
               2. chILD histologically diagnosed&#xD;
&#xD;
                    -  Chronic pneumonitis of infancy (CPI)&#xD;
&#xD;
                    -  Desquamative interstitial pneumonia (DIP)&#xD;
&#xD;
                    -  Lipoid pneumonitis / Cholesterol pneumonia&#xD;
&#xD;
                    -  Nonspecific interstitial pneumonia (NSIP)&#xD;
&#xD;
                    -  PAP after the exclusion of mutations in GMCSF-Ra/b and GMCSF autoantibodies*&#xD;
&#xD;
                    -  Usual interstitial pneumonia (UIP)&#xD;
&#xD;
                    -  Follicular bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia (LIP)&#xD;
&#xD;
                    -  Storage disease with primary pulmonary involvement (e.g. Niemann Pick)&#xD;
&#xD;
                    -  Hermansky-Pudlak Syndrome&#xD;
&#xD;
                    -  Idiopathic pulmonary haemorrhage (haemosiderosis)*&#xD;
&#xD;
                    -  Other histology diagnosing chILD, in particular combination of the above&#xD;
                       pattern, but not exclusively&#xD;
&#xD;
          4. Start block: no HCQ treatment in the last 12 weeks Stop block: stable HCQ treatment&#xD;
             for at least the last 12 weeks&#xD;
&#xD;
          5. Ability of subject or/and legal representatives to understand character and individual&#xD;
             consequences of clinical trial.&#xD;
&#xD;
          6. Signed and dated informed consent of the subject (if subject has the ability) and the&#xD;
             representatives (of underaged children) must be available before start of any specific&#xD;
             trial procedures.&#xD;
&#xD;
        (*may be diagnosed in the absence of a lung biopsy by characteristic lung lavage cytology&#xD;
        (PAS stain, Fe stain), CT pattern or autoantibodies (gliadin, endomysium; cANCA) and&#xD;
        clinical course.)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subjects presenting with any of the following criteria will not be included in the trial:&#xD;
&#xD;
          -  chILD primarily related to developmental disorders&#xD;
&#xD;
          -  chILD primarily related to growth abnormalities reflecting deficient alveolarisation&#xD;
&#xD;
          -  chILD related to chronic aspiration&#xD;
&#xD;
          -  chILD related to immunodeficiency&#xD;
&#xD;
          -  chILD related to abnormalities in lung vessel structure&#xD;
&#xD;
          -  chILD related to organ transplantation/organ rejection/GvHD&#xD;
&#xD;
          -  chILD related to recurrent infections&#xD;
&#xD;
          -  Acute severe infectious exacerbations&#xD;
&#xD;
          -  Known hypersensitivity to HCQ, or other ingredients of the tablets&#xD;
             (lactose-monohydrate, povidone, maize starch, magnesium stearate, hypromellose,&#xD;
             macrogol or titanium dioxide (E 171), silicon dioxide or mannitol), to&#xD;
             sucrose-octaacetate or sodium saccharine.&#xD;
&#xD;
          -  Proven retinopathy or maculopathy&#xD;
&#xD;
          -  Glucose-6-phosphate-dehydrogenase deficiency resulting in favism or hemolytic anemia&#xD;
&#xD;
          -  Myasthenia gravis&#xD;
&#xD;
          -  Hematopoetic disorders&#xD;
&#xD;
          -  Pregnancy and lactation (Women with childbearing potential have to practice a&#xD;
             medically accepted contraception during trial and till three months after the end of&#xD;
             the treatment with HCQ, and a negative pregnancy test (serum or urine) should be&#xD;
             existent on Visit 1, if girls of childbearing age and only if sexual relations are&#xD;
             known or probable. It is at the discretion and responsibility of the attending&#xD;
             physician to decide, whether a pregnancy test is necessary or not. Reliable&#xD;
             contraception are systematic contraceptives (oral, implant, injection). Women that are&#xD;
             sterile by surgery can participate in the trial. At the discretion of the&#xD;
             investigator, sexual abstinence is also accepted as contraceptive method. Girls after&#xD;
             menarche have to receive a counselling about birth control methods in presence of at&#xD;
             least one parent, which has to be documented in the patient notes.&#xD;
&#xD;
          -  Participation in other clinical trials during the present clinical trial or not beyond&#xD;
             the time of 4 half-lives of the medication used, at least one week.&#xD;
&#xD;
          -  Hereditary galactose intolerance, lactase deficiency or glucose-galactose-&#xD;
             malabsorption&#xD;
&#xD;
          -  Renal insufficiency at screening, defined as glomerular filtration rate (GFR)&#xD;
&#xD;
               -  &lt; 40 mL/min/1.73 m2 in patients age 3 to 8 weeks&#xD;
&#xD;
               -  &lt; 60 mL/min/1.73 m2 in patients ≥ 8 weeks of age (KDIGO guideline 2012, K/DOQI&#xD;
                  guideline 2002)&#xD;
&#xD;
          -  Liver disease, gastrointestinal disorder, haematological disorder, epilepsy or other&#xD;
             neurological disorder, psoriasis, porphyria at the discretion of the treating&#xD;
             physician&#xD;
&#xD;
          -  Simultaneous prescription of other potentially nephrotoxic or hepatotoxic medication&#xD;
             at the discretion of the treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elias Seidl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians University Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendmedizin Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph- und St. Elisabeth Hospital gGmbH</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen, Pädiatrische Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin, Klinik für Pädiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

